Merck acquires global rights to SciBrunch Therapeutics’ SPR2015, a preclinical oral KRAS G12D inhibitor, in a deal worth up ...
Merck said on Monday it would pay ​up to $2.13 billion under a global licensing deal with China's SciBrunch Therapeutics for ...
Conversations about cancer research are tough for anyone who has ever been diagnosed, treated, or lost someone to the disease ...
Merck (MRK) stock: company licenses SciBrunch's cancer drug SPR2015 in a deal worth up to $2.13 billion, targeting KRAS G12D mutations.
US FDA approves Welireg plus Lenvima for certain previously treated adult patients with advanced RCC with a clear cell component: Rahway, New Jersey Monday, September 28, 2026, 14 ...
Merck (MRK) acquires worldwide rights to SPR2015 cancer drug from SciBrunch in deal valued at $2.13B, targeting common KRAS ...
Key Points Interested in Moderna, Inc.? Here are five stocks we like better. Moderna plans to pursue regulatory filing for intismeran, its personalized mRNA cancer vaccine developed with Merck, ...
AI drug discovery is about to get a public-market test with unusually recognizable backers. Iambic Therapeutics filed for a U ...
Immunocore Holdings leverages its ImmTAX platform, generating $223m in 1H 2026 revenue and achieving profitability. Read more ...
FinanceBuzz on MSN
Trump's tariffs could double the price of Ozempic and these other drugs
Trump's 100% pharmaceutical tariffs could double prices for common imported medications. Learn which drugs are affected and ...
Ludmir, MD, discussed neoadjuvant radiation, advanced treatment techniques, the HYPERION CCA trial, and lirafugratinib in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results